title: Tigecycline option for the treatment of bone and joint infections caused by multidrug-resistant Staphylococcus epidermidis.
authors.forename: Nathalie
authors.initials: N
authors.lastname: Asseray
authors.forename: Pascale
authors.initials: P
authors.lastname: Bemer
authors.forename: Stéphane
authors.initials: S
authors.lastname: Corvec
authors.forename: David
authors.initials: D
authors.lastname: Boutoille
authors.forename: Sophie
authors.initials: S
authors.lastname: Touchais
authors.forename: Dominique
authors.initials: D
authors.lastname: Navas
mesh_terms: D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001850:Bone Diseases, Infectious / Q000188:drug therapy* / Q000382:microbiology; D024901:Drug Resistance, Multiple, Bacterial; D005260:Female; D006801:Humans; D007592:Joint Diseases / Q000188:drug therapy* / Q000382:microbiology; D008297:Male; D008875:Middle Aged; D008911:Minocycline / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013203:Staphylococcal Infections / Q000150:complications / Q000188:drug therapy*; D013212:Staphylococcus epidermidis / Q000187:drug effects* / Q000502:physiology; D000078304:Tigecycline; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D000078304:Tigecycline; D008911:Minocycline